Skip to main content
TipRanks
Go Ultimate75% OFF

Argenx Se (ARGX) AI Stock Analysis

918 Followers
ARGX

Argenx Se

(NASDAQ:ARGX)

Select Model
Rating:76Outperform
Price Target:$1,105.00▲(16.20% Upside)
Action:reiterated
Date:10/22/26

Overall score reflects standout fundamentals (rapid growth, strong margins, and an exceptionally low-leverage balance sheet) as the primary positive driver, reinforced by a bullish earnings-call outlook with multiple potential 2027 launch catalysts. The score is tempered by mixed/soft technical momentum and execution risk from sharply higher planned operating expenses alongside some pipeline setbacks and uneven historical cash-flow consistency.

Positive Factors
Rapid product growth and marginsSustained product growth, driven by increasing patients served, shows expanding commercial adoption rather than reliance on a single short-term event. Strong operating margins indicate that revenue is scaling faster than expenses, supporting reinvestment and potentially durable earnings growth.
Negative Factors
Sharp operating expense increaseThe planned expense step-up materially raises the investment required to support Forte, FB102, commercial infrastructure and the broader pipeline. Even if strategically justified, this spending can pressure margins and cash generation if launches, approvals or clinical outcomes take longer than expected.

Argenx Se Key Performance Indicators (KPIs)

Revenue By SegmentBreaks down revenue by business segment, offering insight into which areas are driving growth, profitability, and strategic focus.

€0.00€500.00M€1.00B€1.50B€2.00B€2.50BJun 22Dec 22Jun 23Dec 23Jun 24Dec 24Jun 25Dec 25Jun 26
Chart Insights

Product revenue has become the dominant, high‑velocity driver—growing into multi‑billion quarters and absorbing the decline of collaboration receipts—while "Other" is steadily rising, suggesting expanding ancillary revenue or milestone/market openings. The mid‑2025 spike and subsequent dip look like timing/channel or milestone recognition rather than demand loss; management’s latest call (record product sales, broad prescriber adoption and label expansion) reinforces sustainable commercial momentum, but watch rising operating spend and payer/habit barriers that could slow longer‑term penetration.

Data provided by:The Fly

Argenx Se (ARGX) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%ARGX+3.98%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$60.03B
Dividend Yield
―
Average Volume (3M)
366.80K
Price to Earnings (P/E)
45.5
Beta (1Y)
0.31
Revenue Growth
70.57%
EPS Growth
30.28%
Country
US
Employees
1,863
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Argenx Se Business Overview & Revenue Model

Company Description

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United St...

How the Company Makes Money

argenx primarily makes money by commercializing its prescription biologic medicines, generating revenue from product sales to healthcare providers and distributors in the regions where its therapies are approved and reimbursed. A major revenue stream...

Argenx Se Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:6.84%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by 54% year-over-year product sales growth, continued momentum in both MG and CIDP, positive ALKIVIA and FB102 data, a broadening pipeline and expectations for up to five potential launches in 2027. The main challenges were the dermatomyositis confirmatory-trial requirement, the Sjögren's futility outcome, elevated planned operating expenses and limited formal revenue guidance, but these issues were outweighed by the company's commercial performance, financial strength and pipeline progress.

Positive Updates

Strong Third-Quarter Revenue Growth
Product net sales reached $1.7 billion, up 54% year-over-year and 13% quarter-over-quarter. Growth in the number of patients served continued to drive revenue performance.

Negative Updates

Dermatomyositis Filing Requires Additional Confirmatory Evidence
The company said the dermatomyositis study missed its primary endpoint. Although the magnitude of the effect was consistent with the immune-mediated necrotizing myopathy results, the FDA viewed the data as hypothesis-generating and requiring confirmatory evidence. The company is designing an additional registrational trial and has not yet disclosed its duration or final design.

Company Guidance

Management expects 10 molecules in clinical development by the end of this year, combined R&D and SG&A expenses of approximately $4 billion for 2026, a 45% increase year-over-year from 2025, and for 2027 said, “please do not assume another 45% increase,” with investors to “Think of about half of that 45% if you need something for your models now”; more guidance is expected at JPMorgan. The company expects 5 potential launches across its portfolio in 2027, or “up to 5 launches in a single year in the U.S.,” including a pediatric MG PDUFA date of February 2027, a VYVGART Hytrulo auto-injector in the second half of 2027, an IMNM sBLA by year-end, and potentially MMN following the EMPASSION readout in December and a priority-review application if data are positive. Management expects about 2 quarters after approval to get payer policies in place for IMNM, expects 10 clinical-stage molecules by the end of this year, is “well on track” for 10 labeled indications and 5 molecules in Phase III development by the end of the decade, and reiterated Vision 2030 targets of 50,000 patients by the end of the decade.

Argenx Se Financial Statement Overview

Summary

Strong financial profile led by a sharp profitability inflection and rapid revenue acceleration (2025 revenue +81.5% YoY) with very high margins (gross ~89%, operating ~23%, net ~31%). Balance sheet strength is exceptional with minimal leverage (debt-to-equity ~0.01) and growing equity base, supporting continued R&D and commercialization. Main constraint is durability/quality of cash generation: cash flows were negative in 2021–2024 and 2025 cash conversion (operating cash flow vs. net income) is not yet consistently strong.

Income Statement

86Very Positive

Balance Sheet

95Very Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.02B4.15B2.19B1.23B410.75M1.08B
Gross Profit5.40B3.70B1.96B1.11B381.31M497.28M
EBITDA1.87B1.31B105.17M-192.28M-622.78M-392.78M
Net Income1.89B1.29B833.04M-295.05M-709.59M-408.26M
Balance Sheet
Total Assets10.03B8.68B6.20B4.54B3.13B2.85B
Cash, Cash Equivalents and Short-Term Investments5.18B4.44B3.38B3.18B2.19B2.34B
Total Debt47.00M83.49M39.05M20.00M12.43M11.46M
Total Liabilities1.61B1.36B704.24M444.95M320.56M316.05M
Stockholders Equity8.42B7.32B5.50B4.10B2.81B2.53B
Cash Flow
Free Cash Flow1.16B844.30M-151.05M-464.14M-966.63M-728.25M
Operating Cash Flow1.16B850.49M-82.75M-420.33M-862.81M-606.81M
Investing Cash Flow70.75M823.88M-717.59M308.21M-461.18M-347.07M
Financing Cash Flow262.43M233.73M279.76M1.34B843.76M1.12B

Argenx Se Technical Analysis

Technical Analysis SentimentPositive
Last Price950.95

Price Trends

50DMA923.88Positive
100DMA923.20Positive
200DMA860.28Positive

Market Momentum

MACD18.56Negative
RSI58.77Neutral
STOCH88.60Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARGX, the sentiment is Positive. The current price of 950.95 is above the 20-day moving average (MA) of 907.57, above the 50-day MA of 923.88, and above the 200-day MA of 860.28, indicating a bullish trend. The MACD of 18.56 indicates Negative momentum. The RSI at 58.77 is Neutral, neither overbought nor oversold. The STOCH value of 88.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARGX.

Argenx Se Risk Analysis

Argenx Se disclosed 60 risk factors in its most recent earnings report. Argenx Se reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.We have benefitted from certain research and development incentives. These could be impacted by changes in law (or interpretation), changes of fact (such as a change in ownership), or challenge by tax authorities.Q4, 2023

Argenx Se Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ARGX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
REGNREGN81Outperform$98.82B20.3515.07%0.39%18.59%8.14%
ARGXARGX76Outperform$60.89B45.5016.86%―70.57%30.28%
GMABGMAB63Neutral$30.47B42.8012.26%―19.61%-50.40%
XNCRXNCR61Neutral$2.78B-23.62-21.29%―33.55%11.51%
IMVTIMVT53Neutral$7.07B-13.35-63.01%――9.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ZYMEZYME48Neutral$1.83B39.1622.48%―97.78%―

* Healthcare Sector Average

Performance Comparison

0%50%100%ARGXREGNXNCRZYMEGMABIMVTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ARGX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ARGXArgenx950.9532.423.53%
REGNRegeneron Pharmaceuticals952.40230.7631.98%
XNCRXencor Inc.35.4019.38120.97%
ZYMEZymeworks26.453.4615.05%
GMABGenmab (Otc)51.5721.2570.09%
IMVTImmunovant, Inc.33.289.5940.48%

Argenx Se Corporate Events

Argenx Unveils New VYVGART and Pipeline Data at AANEM and MGFA

Sep 29, 2026

On September 29, 2026, Argenx reported new clinical and real‑world data for VYVGART in myasthenia gravis and CIDP, presented at the AANEM and MGFA meetings in Orlando. The results show deeper improvement in ocular MG with additional treatment cycles,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 22, 2026